SciSparc Ltd Ordinary Shares SPRC 深 滬
等待開盤 09-11 09:30:00 美东时间
1.81
+0.010
+0.56%
華盛通- 最 高1.93
- 今 開1.79
- 成交量 19.57万股
- 最 低 1.75
- 昨 收 1.80
- 總市值 2031.87万
- 52周最高 37.59
- 市盈率 靜 --
- 換手率 1.74%
- 52周最低 1.75
- 委 比 60.00%
- 總股本 1122.58万
- 歷史最高 3865.68
- 量 比 0.91
- 振 幅 10.00%
- 歷史最低 1.75
- 每 手 1
- 風險率 2.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SciSparc Ltd. Reports AutoMax Investigation by Israeli Authorities
SciSparc Ltd. ( ($SPRC) ) has shared an announcement. On September 7, 2025, inv...
09-09 04:28
SciSparc Ltd. Converts Debentures into Equity, Issuing New Shares
SciSparc Ltd. ( ($SPRC) ) just unveiled an update. In August 2025, SciSparc Ltd...
08-29 19:55
SciSparc Shareholders Approve Merger With AutoMax, Expanding Into Israel's Electric Vehicle Market
SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that
08-28 18:46
SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
SciSparc Ltd.宣布，其与AutoMax Motors Ltd.的合并已获双方股东批准。此战略合并将通过反向并购完成， SciSparc将持有AutoMax 100%的股份，合并后SciSparc股东持有约50.01%的股份。该合并旨在扩展SciSparc的业务至汽车领域，特别是通过AutoMax的平行进口业务进入电动车市场。SciSparc已为AutoMax提供了财务支持，并期望通过此举实现长期战略目标，即多元化业务并把握以色列电动车市场增长机遇。交易仍需获得以色列法院批准。
08-28 13:24
SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
SciSparc Ltd. announced that its shareholders have approved a proposed merger with AutoMax Motors Ltd., a leading parallel vehicle importer in Israel. The merger, which was agreed upon in April 2024, will allow SciSparc to acquire 100% of AutoMax’s shares through a reverse merger. After the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company’s shares. This strategic move aims to expand SciSparc’s operat...
08-28 10:45
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) shares rose 34.6% to $0.7 during Friday's a...
08-23 05:07
Clearmind Medicine Publishes International Patent Application For Therapy Targeting Obesity And Metabolic Syndrome In Collaboration With SciSparc
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
08-07 19:39
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
SciSparc Ltd., a clinical-stage pharmaceutical company, has made progress toward its proposed merger with AutoMax Motors Ltd., Israel's leading electric vehicle importer. The merger, announced in April 2024, involves a reverse merger with SciSparc acquiring 100% of AutoMax's shares. Shareholder meetings to approve the merger will take place on August 25 and 28, 2025, with U.S. SEC approval already granted. SciSparc focuses on cannabinoid-based th...
07-30 20:34
SciSparc And Clearmind File International Patent For Novel Obesity And Liver Disease Treatment Combining MEAI and PEA
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,
07-30 20:13
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. and Clearmind Medicine Inc. have filed a new international patent application for their innovative combination therapy targeting obesity and MASLD. The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), leveraging its unique pharmacological properties. The collaboration aims to address significant global health challenges, with obesity affecting over 890 million people and NAFLD...
07-30 12:12
